Wild-type and modified gp100 peptide-pulsed dendritic cell vaccination of advanced melanoma patients can lead to long-term clinical responses independent of the peptide used

Willem Lesterhuis, G. Schreibelt, N.M. Scharenborg, H.M.-I.H. Brouwer, M.-J.P. Gerritsen, S. Croockewit, P.G. Coulie, R. Torensma, G.J. Adema, C.G. Figdor, I.J.M. De Vries, C.J.A. Punt

    Research output: Contribution to journalArticlepeer-review

    62 Citations (Scopus)
    Original languageEnglish
    Pages (from-to)249-260
    JournalCancer Immunology Immunotherapy
    Issue number2
    Publication statusPublished - 2011

    Cite this